Spiolto Respimat approved in first EU countries for COPD

• Spiolto^® Respimat^® is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
• Spiolto^® Respimat^® provides significant improvements in lung function, breathlessness, quality of life and rescue medication use over Spiriva^® right from the initial stages when patients need maintenance therapy. These additional benefits could enable patients to remain active and avoid the downward spiral of COPD for as long as possible.

COPD is a chronic, progressive, treatable but incurable lung disease that affects 210 million people worldwide and is predicted to become the 3rd leading cause of death by 2030. Patients are typically diagnosed when lung function is already significantly impaired and maintenance therapy is needed. They suffer from symptoms including breathlessness and coughing that often stop them from being active. This can lead to a downward spiral of worsening symptoms and even further inactivity, contributing to an increased risk of disability and death.